# US 8,465,913 B2 · Mitochondrial function of prohibitin 2 (PHB2)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,913 B2
- Document ID: US8465913B2
- Status: Granted
- Kind: B2
- Application number: 13/402,933
- Filed: 2012-02-23
- Published: 2012-08-02
- Granted: 2013-06-18
- Earliest claimed: 2005-11-24
- Assignees: Jichi Medical University
- Applicants: Hitoshi Endo; Katsumi Kasashima
- Inventors: Hitoshi Endo; Katsumi Kasashima
- Web page: https://patentgrep.com/patent/US8465913B2

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- G01N 33/5079: {Mitochondria}
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2333/4703: Regulators; Modulating activity
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.

## Claims

### Claim 1

A method for screening for an agent for regulating a capability of a PHB2 protein to interact with a protein that is encoded by a gene selected from the group consisting of a VDAC2 gene, a Hax-1 gene, an ANT2 gene and an OPA1 gene, the method comprising:
contacting cells expressing a PHB2 gene with a candidate substance by adding the candidate substance to a culture comprising the cells; and
determining that the candidate substance is the agent for regulating the capability of the PHB2 protein to interact with the protein that is encoded by the gene selected from the group consisting of the VDAC2 gene, the Hax-1 gene, the ANT2 gene and the OPA1 gene if the candidate substance regulates the capability of the PHB2 protein to interact with the protein that is encoded by the gene selected from the group consisting of the VDAC2 gene, the Hax-1 gene, the ANT2 gene and the OPA1 gene in the cells expressing the PHB2 gene caused to come into contact with the candidate substance, when the cells are compared with cells expressing the PHB2 gene in the absence of the candidate substance.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the capability to interact is the capability to form a complex.